ClinicalTrials.gg
Status unknownNCT02072031Updated Apr 26, 2016

Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma(RCC)

A Phase 2 interventional study of Anlotinib and Sunitinib maleate in Anlotinib and RCC, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-26.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2016), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to compare the efficacy and safety profile between Anlotinib and Sunitinib in patients with advanced Renal Cell Carcinoma(RCC).

02

Conditions studied

  • Anlotinib
  • RCC

Keywords

  • Anlotinib
  • Sunitinib
  • Renal Cell Carcinoma(RCC)
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Patients with confirmed advanced renal cell carcinoma including clear cell component and not available for surgery
  • 2.Without drug treatment for RCC or chemotherapy/cytokine therapy failure or resistant patients)
  • 3.With (using RECIST1.1)
  • 4.18-75years, PS:0-1, of more than 3 months
  • 5.Other cytotoxic drugs,radiation therapy,or surgery≥4 weeks
  • 6.main organs function is normal
  • 7.Signed and dated

Exclusion criteria

Exclusion Criteria:

  • 1.Previously received targeted therapy of the renal cell carcinoma (such as sunitinib, Sorafenib)
  • 2.patients has many influence factors toward oral medications
  • 3.Known
  • 4.patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade I myocardial infarction, arrhythmias and Class I heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (FBG)>10mmol/L);urine protein≥++,etc.
  • 5.patients failed to heal wounds or fractures for Long-term
  • 6.patients occurred venous thromboembolic events within 6 months
  • 7.patients has -positive or organ transplantation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
133 participants (estimated)

Study arms

  • Experimental
    Anlotinib

    Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: Anlotinib

  • Active comparator
    Sunitinib maleate

    Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.

    Drug: Sunitinib maleate

Interventions

  • Anlotinib p.o. qd

  • DrugSunitinib maleate

    Sunitinib 50 mg p.o. qd

06

What researchers measure

Primary outcomes

  1. Progress free survival (PFS)

    The PFS time is defined as time from randomization to locoregional or systemic recurrence, second malignancy or death due to any cause; censored observations will be the last date of: "death", "last tumor assessment", "last follow up date" or "last date in drug log".

    Time frame: each 42 days up to PD or death(up to 36 months)

Secondary outcomes

  1. Objective Response Rate

    To evaluate the effectiveness of Anlotinib Hydrochloric Capsule by enhanced CT/MRI scan every two cycles or Sunitinib maleate by enhanced CT/MRI scan every cycle. Objective Response Rate (ORR) is defined as participants who had complete response (CR) or partial response(PR) divided by the total number of patients.

    Time frame: each 42 days up to intolerance the toxicity or PD (up to 36 months)

  2. Disease Control Rate (DCR)

    To evaluate the effectiveness of Anlotinib Hydrochloric Capsule by enhanced CT/MRI scan every two cycles or Sunitinib maleate by enhanced CT/MRI scan every cycle. Disease Control Rate (DCR) defined as the percentage of participants with Disease Control best overall response (complete response, partial response or stable disease).

    Time frame: each 42 days up to intolerance the toxicity or PD (up to 36 months)

  3. Overall Survival (OS)

    OS was defined as time from date of randomization to date of death due to any cause. For participants still alive at the time of analysis, OS time was censored on last date that participants were known to be alive.

    Time frame: From randomization until death (up to 36 months)

07

Study locations

15 sites
  • Peking Union Medical College Hospital
    Beijing, Beijing 100005, China
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing 404100, China
  • Gansu Province Tumor Hospital
    Lanzhou, Gansu 730050, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510000, China
  • Guangxi medical university affiliated tumor hospital
    Nanning, Guangxi 530021, China
  • Harbin medical university affiliated tumor hospital
    Haerbin, Heilongjiang 150000, China
  • The 81st Hospital of Chinese PLA
    Nanjing, Jiangsu 210000, China
  • Jilin Cancer Hospital
    Changchun, Jilin 132000, China
  • China General Hospital of Shenyang Military Region
    Shenyang, Liaoning 110000, China
  • Liaoning Province Tumor Hospital
    Shenyang, Liaoning 110042, China
  • Qilu Hospital,Shandong University
    Jinan, Shandong 250012, China
  • Cancer Hospital of Fudan University
    Shanghai, Shanghai 200000, China
  • West China Hospital,Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Hospital
    Tianjin, Tianjin 300000, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2014
First posted
Feb 26, 2014
Start
Dec 2013
Primary completionEst.
Dec 2016
CompletionEst.
Dec 2016
Last update
Apr 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02072031
Responsible party
Sponsor
First posted
Feb 26, 2014
Start date
Dec 2013
Primary completion
Dec 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Apr 26, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion